gmg updat drive stori
build toward strateg goal compani provid increment updat across
pipelin effort advanc strateg goal becom global integr
immunolog compani argx well capit cash/equival continu
execut broad develop plan efgartigimod across indic fifth
expect announc five registr trial on-going
despit addit asset expect enter clinic advanc cusatuzumab
hematolog malign short-term driver stock remain gmg indic
focu remain gmg fcrn catalyst sc formul recent
inbound weve get name around expect gmg trial
readout potenti read-through argx competitor updat indic
data expect nipocalimab phase data expect
major investor weve spoken agre view
design fairli de-risk clinic perspect sinc doesnt introduc unknown
shift dose regimen success trial though question
commerci side remain argx advantag potenti first-to-market
gmg iv formul launch expect though see rapid follow-on sc
introduct import argx maintain long-term market share rel
crowd field think stock reflect substanti option efgartigimod current
level expect around program rel low given earli
stage see recent announc decis alexion discontinu program
increment posit argx remov potenti sc competitor field
argenx develop enhanz sc formul efgartigimod bridg
strategi gmg tbd meet regul discuss option
model updat adjust model reflect actual revis near-term
expens project ep vs prior risk clinic
regulatori commerci acquisition/merg
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
argenx se biotechnolog compani develop antibody-bas
therapi treatment autoimmun diseas cancer
product includ efgartigimod treatment autoimmun diseas
cusatuzumab treatment aml
blue sky valuat base posit phase gmg
readout efgartigimod po de-risk addit
efgartigimod indic itp/pv po
 weigh
grey sky valuat base unexpect safeti issu
render efgartigimod uncompetit po efgartigimod
program weigh
 close
compani mention price
tiago fauth certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
